{
  "hypothesis": "h248",
  "title": "Endothelin Antagonist + Prostacyclin Heart Failure Safety Filter",
  "analysis_date": "2026-02-05",
  "heart_failure_impact": {
    "total_hf_predictions": 90,
    "original_high_confidence": 30,
    "excluded_contraindicated": 7,
    "corrected_high_confidence": 23,
    "percentage_fp_removed": 23.3
  },
  "cardiovascular_impact": {
    "total_high_confidence": 60,
    "excluded": 7,
    "percentage_improvement": 11.7
  },
  "excluded_predictions": [
    {
      "drug": "Bosentan",
      "disease": "chronic heart failure",
      "original_tier": "HIGH"
    },
    {
      "drug": "Iloprost",
      "disease": "chronic heart failure",
      "original_tier": "HIGH"
    },
    {
      "drug": "Epoprostenol",
      "disease": "chronic heart failure",
      "original_tier": "HIGH"
    },
    {
      "drug": "Selexipag",
      "disease": "chronic heart failure",
      "original_tier": "HIGH"
    },
    {
      "drug": "Ambrisentan",
      "disease": "chronic heart failure",
      "original_tier": "HIGH"
    },
    {
      "drug": "Treprostinil",
      "disease": "chronic heart failure",
      "original_tier": "HIGH"
    },
    {
      "drug": "MACITENTAN",
      "disease": "chronic heart failure",
      "original_tier": "HIGH"
    }
  ],
  "filter_rules_added": [
    "Endothelin antagonists (Bosentan, Ambrisentan, Macitentan) + heart failure = EXCLUDED",
    "Prostacyclin analogs (Epoprostenol, Treprostinil, Iloprost, Selexipag) + heart failure = EXCLUDED"
  ],
  "clinical_evidence": {
    "endothelin_antagonists": {
      "trials": [
        "ENABLE",
        "MELODY",
        "SERENADE"
      ],
      "harm": "Fluid retention, peripheral edema, no clinical benefit"
    },
    "prostacyclin_analogs": {
      "trials": [
        "FIRST"
      ],
      "harm": "INCREASED MORTALITY - trial terminated early"
    }
  }
}